Amarantus to Present at the 3rd Annual Marcum MicroCap Conference
May 27 2014 - 7:27AM
Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology
company focused on the discovery and development of novel
diagnostics and therapeutics related to endoplasmic reticulum
stress, cell cycle dysregulation, neurodegeneration and apoptosis,
today announced that Gerald E. Commissiong, President and CEO will
present at the 3rd Annual Marcum MicroCap Conference on Thursday,
May 29, 2014 at the Grand Hyatt Hotel in New York.
The Company's presentation is scheduled to begin at 10:30 AM EDT
and will be available via a live webcast. To access the webcast,
please go to
http://wsw.com/webcast/marcum2/ambs.
There will be an opportunity for investors to meet one-on-one
with management. Interested investors should contact our Investor
Relations department at ir@amarantus.com.
The annual Marcum MicroCap Conference is a signature showcase
for superior quality, under-followed public companies with less
than $500 million in market capitalization. For more information or
to register, please visit the conference website at
http://www.marcumllp.com/microcap.
About Amarantus
Amarantus is a biotechnology company developing treatments and
diagnostics for diseases associated with neurodegeneration and
protein misfolding-related apoptosis. The Company has licensed
Eltoprazine a phase 2b ready indication for Parkinson's Levodopa
induced dyskinesia. The Company has an exclusive worldwide license
to the Lymphocyte Proliferation test ("LymPro Test®") for
Alzheimer's disease and owns the intellectual property rights to a
therapeutic protein known as Mesencephalic-Astrocyte-derived
Neurotrophic Factor ("MANF") and is developing MANF-based products
as treatments for brain disorders. Amarantus is a Founding Member
of the Coalition for Concussion Treatment (#C4CT), a movement
initiated in collaboration with Brewer Sports International seeking
to raise awareness of new treatments in development for concussions
and nervous-system disorders. The Company also owns intellectual
property for the diagnosis of Parkinson's disease ("NuroPro") and
the discovery of neurotrophic factors ("PhenoGuard"). For further
information please visit www.Amarantus.com, or connect with the
Company on Facebook, LinkedIn, Twitter and Google+.
About Marcum LLP
Marcum LLP is one of the largest independent public accounting
and advisory services firms in the United States. Ranked #15
nationally, Marcum LLP offers the resources of 1,300 professionals,
including over 160 partners, in 23 offices throughout the U.S.,
Grand Cayman and China. Headquartered in New York City, the Firm's
presence runs deep, with full-service offices strategically located
in major business markets. Marcum is a member of the Marcum Group,
an organization providing a comprehensive range of professional
services spanning accounting and advisory, technology solutions,
wealth management, and executive and professional recruiting. The
Marcum Group companies include Marcum LLP; Marcum Technology LLC;
Marcum Search LLC; Marcum Financial Services LLC; Marcum Bernstein
& Pinchuk LLP; MarcumBuchanan Associates LLC; and Marcum Cronus
Partners LLC. For more information, visit www.marcumllp.com.
Certain statements, other than purely historical information,
including estimates, projections, statements relating to our
business plans, objectives, and expected operating results, and the
assumptions upon which those statements are based, are
forward-looking statements." These forward-looking statements
generally are identified by the words believes," project,"
expects," anticipates," estimates," intends," strategy," plan,"
may," will," would," will be," will continue," will likely result,"
and similar expressions. Forward-looking statements are based on
current expectations and assumptions that are subject to risks and
uncertainties which may cause actual results to differ materially
from the forward-looking statements. Our ability to predict results
or the actual effect of future plans or strategies is inherently
uncertain. Factors which could have a material adverse effect on
our operations and future prospects on a consolidated basis
include, but are not limited to: changes in economic conditions,
legislative/regulatory changes, availability of capital, interest
rates, competition, and generally accepted accounting principles.
These risks and uncertainties should also be considered in
evaluating forward-looking statements and undue reliance should not
be placed on such statements.
CONTACT: Investor/Media Contacts
Aimee Boutcher, Director of Investor Relations
Amarantus Bioscience Holdings, Inc.
408-737-2734 x 101
ir@amarantus.com
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Apr 2024 to May 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From May 2023 to May 2024